搜索筛选:
搜索耗时4.3564秒,为你在为你在102,285,761篇论文里面共找到 6 篇相符的论文内容
发布年度:
Hsp90 N-terminal inhibitor 17-AAG and C-terminal inhibitor cisplatin synergistically eradicates Bcr-
[会议论文] 作者：Lixian Wu,Jianhua Xu,Lisen Huang,Ruijia Chen,Meijuan Huang,Yuanzhong Chen,
来源：2012医学科学前沿暨第二届个体化治疗与抗肿瘤药物研究新趋向研讨会 年份：2012
Hsp90 is a ubiquitous molecular chaperone that regulates over 200 client proteins involved in multiple growth and signaling pathways,which are targets for chemotherapeutic strategies.Thus,Hsp90s role...
[会议论文] 作者：Lixian Wu,Jianhua Xu,Lisen Huang,Ruijia Chen,Meijuan Huang,Yong Wu,YuanzhongChen,
来源：2013医学前沿论坛暨第十三届全国肿瘤药理与化疗学术会议 年份：2013
...
[会议论文] 作者：Lixian Wu,Jianhua Xu,Lisen Huang,Ruijia Chen,Meijuan Huang,Yong Wu,YuanzhongChen,
来源：2013医学前沿论坛暨第十三届全国肿瘤药理与化疗学术会议 年份：2013
Heat shock protein 90 (Hsp90) is a promising target for chemotherapy based on its chaperone function in regulating many tumor-related client proteins.Hsp90 contains amino(N-) and carboxyl(C-) terminal...
C086 inhibits proliferation of imatinib-resistant CML cells that express wild-type or mutant Bcr-Abl
[会议论文] 作者：Ruijia Chen,Lixian Wu,Jianhua Xu,Y angLiu,Liguang Lou,Ying Wu,Lisen Huang,Meijuan Huang,Yong Wu,Yuanzhong,
来源：2013医学前沿论坛暨第十三届全国肿瘤药理与化疗学术会议 年份：2013
...
C086 inhibits proliferation of imatinib-resistant CML cells that express wild-type or mutant Bcr-Abl
[会议论文] 作者：Ruijia Chen,Lixian Wu,Y angLiu,Liguang Lou,Ying Wu,Lisen Huang,Meijuan Huang,Yong Wu,Yuanzhong Chen,Jianhua,
来源：2013医学前沿论坛暨第十三届全国肿瘤药理与化疗学术会议 年份：2013
Imatinib mesylate is a successful treatment for chronic myeloid leukaemia (CML),but resistance to this drug has been observed.The most common resistance mechanism involves mutations in the Bcr-Abl kin...
Curcumin and its Derivatives Potently Inhibits the T3151 Mutant and Overcomes Mutation-Based Resista
[会议论文] 作者：Lixian Wu,Yuanzhong Chen,Jianhua Xu,Yang Liu,Kunzhong Zhang,Ying Wu,Liguang Lou,Ruijia Chen,Lisen Huang,
来源：2012医学科学前沿暨第二届个体化治疗与抗肿瘤药物研究新趋向研讨会 年份：2012
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML),but resistance attributable to kinase domain mutations can lead to relapse.Mutation of...
相关搜索：
